SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?


To: Jim Willie CB who wrote (48573)3/11/2002 6:36:52 AM
From: stockman_scott  Respond to of 65232
 
Biotech turns eye to agricultural, industrial fields

Midwest firms in line to ride wave, researchers say
By Jon Van
Chicago Tribune staff reporter
Published March 11, 2002

The Midwest may have missed the first biotechnology wave, but it is well positioned to capture a big piece of the next waves that are just gathering speed, said James Frank, director of biotech applications at Argonne National Laboratory.

The first biotech wave centered on medical applications, Frank said, and while there are many Midwest-based biotech firms in this space, the field is dominated by East and West Coast-based companies.

The next applications for biotechnology will focus on agricultural and industrial processes, he said, and the Midwest has a clear chance to dominate these fields.

Speaking Friday at a meeting of the Chicago Technology Forum, Frank said that whole industries may undergo changes spawned by new biotech developments. One example is the chemical industry that traditionally has been based upon petrochemicals.

"These days, new petrochemical plants are being built in foreign countries to be close to the source of oil," he said. "There is growing interest here in making chemicals from agricultural products instead of petroleum."

Argonne researchers have been working for years to make industrial solvents from natural products instead of petrochemicals because they are non-toxic and don't pose the environmental problems of traditional solvents. The challenge has been designing processes to produce the "green" solvents more economically than traditional petrochemical refining.

One fledgling company based upon Argonne's biotech research is Advanced Chromatography Systems, which has been started by Argonne staff and graduate business students at the University of Chicago.

ACS is developing processes to purify industrial materials by using specially designed membranes and electricity. Argonne's process doesn't require chemical baths to clean and recharge the system as is common with current industrial technology.

Sam Nickerson, acting chief executive of ACS, said the technology is in its early stages but it already promises to reduce operating costs by 40 percent and slash the use of chemicals in purification operations by 90 percent.

Other start-up companies also explained their goals at the technology forum, which was organized by several Illinois-based universities with the support of government officials to promote the growth of tech industries here.

ChemSensing Inc. has developed technology that converts aromas into color changes that can be seen by humans.

"It gives humans a means of using our vision to see things that dogs can smell," said Kenneth Suslick, a chemistry professor at the University of Illinois at Urbana-Champaign who devised the technology's underlying chemistry.

Products that will use a person's breath to help physicians diagnose illness are a goal of the firm, but its immediate applications have been less ambitious. The firm has worked with personal products firms to make simple test kits that let people determine when they have bad breath or body odor. Other applications are food labels that will change color if the products go bad.

Traditional biotech goals of identifying compounds that will make effective new drugs are sought by two other young firms that addressed the tech meeting.

Nyxis Neurotherapies Inc. has technology that can identify molecules that modify neurons to mute the pain generated by injured nerves. Using this process, which was developed at Northwestern University, Nyxis has identified several compounds that may yield useful drugs, said Joseph Moskal, a neurobiology professor at Northwestern.

One compound is already a candidate for human trials to establish its safety, he said.

The fundamental knowledge that has produced several possible candidates is exciting, Moskal said, because there are very few treatments available for nerve-based pain.

The Senex Biology Corp. is seeking cancer therapies based upon new information about proteins produced by cells that have become aged. These cells, which no longer divide to form new cells, produce proteins that both inhibit and promote cancer, said Igor Roninson, head of molecular oncology at the University of Illinois at Chicago.

Roninson's discoveries may lead not only to new ways of treating cancer, but also new treatments for afflictions associated with aging such as Alzheimer's disease, arthritis and atherosclerosis.

Copyright © 2002, Chicago Tribune



To: Jim Willie CB who wrote (48573)3/11/2002 12:56:52 PM
From: jmanvegas  Read Replies (1) | Respond to of 65232
 
JWCB: I'll get back to you about my thoughts on gold, but take a look at TRMS in the biotech area regarding HIV. They are on the cusp (going into Phase III) on something huge in that area. This could be the sleeper of all biotechs if what I read about their HIV candidates have to offer.

jmanvegas



To: Jim Willie CB who wrote (48573)3/11/2002 1:51:24 PM
From: stockman_scott  Read Replies (1) | Respond to of 65232
 
How Could I Be So Stupid?...

----------------------------------------
Morgan Stanley's Global Economic Forum

Mar 11, 2002
How Could I Be So Stupid?
- Stephen Roach / Morgan Stanley

I’ll never forget the sage advice of my first boss, the legendary Arthur
Burns, Chairman of the Federal Reserve in the 1970s. "Son," he said
through pipe-clenched teeth nearly 30 years ago, "never under-estimate
the inherent resilience of the US economy." Obviously, it’s a piece of
advice I have long since forgotten on my own personal journey. Yes, I
nailed the recession call of 2001. But I seem to have forgotten what
always comes next -- cyclical recovery. How could I be so stupid?

Forgive me, if I indulge in a bout of self-flagellation. But I have always
felt that we learn more from our mistakes than from those ever-fleeting
successes. Don’t get me wrong, I am not abandoning my call for a
double-dip recession in the United States. I still think there is a
compelling case in favor of a relapse later this year -- but obviously one
that would come later and off a higher level of economic activity than I
had thought. But the feedback is not exactly encouraging these days --
from the markets, the clients, and even the guys down the hall. I think
I am probably the last living economist in America to still embrace the
possibility of a double dip -- or for that matter even a subdued or
sluggish recovery (a.k.a. the Nike swoosh). One good thing about my
approach to economics, if I could be so bold to say, is that it is very
transparent. What you see is what you get. It’s an analytically driven
approach that rests on a set of very clear assumptions. As such, it
enables me to understand the whys of my mistakes with painful clarity.
And so I ask myself, What is it that is so flawed about my prognosis?

If my basic view of the economy turns out to be as wrong-footed as
most now suspect, I would argue that I must have five basic
assumptions dead wrong.

First, I must have missed the mark on the
character of this business cycle. I have long argued that this is a
capital-spending-led downturn that reflected the unwinding of excesses
on the supply side of the macro equation brought about by the equity
bubble. As such, I have viewed the US economy as laboring under the
weight of a series of post-bubble aftershocks brought about by low
saving, excess debt, a lingering capacity overhang, and a massive
current-account deficit. While few can dispute the facts of capital
spending leadership to the recent cyclical downturn, maybe that just
doesn’t matter as much as I had thought. After all, the inventory cycle is
alive and well -- the most salient characteristic of any business cycle.
Maybe that matters more than the unusual mix of final demand
weakness in the recent downturn.

Second, I seem to have forgotten the four most important words in
modern-day financial market history -- don’t fight the Fed. The 475 bp
of monetary easing of 2001 was staggering in both its speed and
magnitude. In the eyes of most, the resulting surge in liquidity meant it
was only a matter of time before the economy responded. It must have
been the lags I missed -- that long and variable response time between
rate cuts and the credit-sensitive sectors of the economy. I guess I was
so hung up on the excesses on the supply side -- a capacity overhang
that had to be worked off, irrespective of any level of real short-term
interest rates -- that I lost sight of how quickly monetary easing must
have fed through to the rest of the real economy.

Third, it also appears that I committed the cardinal forecasting error of
betting against the American consumer. I should have known better.
After all, Arthur Burns also warned me never to count out the American
consumer. Unfortunately, he issued that warning in the mid-1970s --
right on the brink of the worst consumer-led recession in post-World
War II history. Never mind, today’s American consumer keeps on
spending in the face of terrible macro fundamentals -- rock-bottom
saving rates, record debt loads, faltering wage income growth, mounting
layoffs, and depleted equity wealth. The ever-clever American consumer
appears to have figured out a way around any conceivable type of
adversity. Lower energy prices, modest tax cuts, and home mortgage
refinancing appear to have been more than offsetting. How could I have
missed that?

Fourth, I may have been too hard on Corporate America. Sure, the US
just went through the worst earnings recession in more than 50 years.
And the Enron debacle has raised profound questions about earnings
quality. But that’s not the end of the world for a nation that is the
champion of creative destruction. After all, ever-nimble corporate
managers have been quick to respond to economic adversity -- cutting
costs with seemingly reckless abandon. Capital spending programs have
been slashed, inventories pruned, and headcounts reduced -- at least
for the non-managerial piece of the workforce. This is quintessential
cost-cutting that paves the way for a big rebound in earnings -- and
concomitant increases in hiring and capital spending. Never mind that
the business community doesn’t exactly see it that way. Economists
always know better.

Fifth, I must have blown the global angle as well. All this stuff about
America’s massive current account deficit and an overvalued dollar just
has to be wrong. The world is more than willing to condone another
spurt of US-led global growth. After all, who else could be the world’s
growth engine? Never mind that America might have to attract close to
$2 billion of foreign capital per day in 2003 to finance its external
imbalance. The US had done it before, and it will do it again. After all,
just consider the alternatives. Europe? Japan? Not a chance on either
count. America wins hand down for a seventh year in a row. The US
needs to keep its great domestic demand machine humming. How else
can the export-led strain of growth elsewhere in the world ever get going
again? I can’t believe I was dumb enough to miss that basic point as
well.

All right, so let me tell you what I really think. Forgive me if I dare
challenge the "Big Mo" and run against the grain of the numbers and
the markets. But I still like the same old story I’ve been telling for
some time. I think the unique capital-spending-led character of this
business cycle will ultimately be decisive in shaping a very subdued
growth outcome for the US economy in the years ahead. Double dip or
not, today’s post-bubble headwinds are every bit as powerful as those
which held back the vigor of recovery for 2 1/2 years in the early 1990s.
Nor do I believe the Fed can do much to change the endgame. An
economy plagued with excess supply is far less responsive to monetary
stimulus than is an economy saddled with inadequate demand.
Moreover, since two of the economy’s most interest rate-sensitive
sectors -- consumer durables and homebuilding -- held up amazingly
well in the downturn, there’s not much upside from these classic drivers
of a Fed-induced recovery. That leaves unanswered the key question of
the recovery call: What sector will spark the rebound?

As for the American consumer, time will obviously tell. But in my book,
over-extended consumers have simply run out of rope. If we’re in a
vigorous recovery, the refi and energy price breaks will most assuredly
go the other way. And I dare say cost-conscious businesses will be
reluctant to add to add aggressively to payroll expenses -- either
through hiring or wage concessions. Sorry, but that will crimp household
purchasing power -- long the key driver of consumer demand. There’s
also a key demographic point that has long concerned me: As the
saving-short and aging American consumer now closes in on retirement,
the increased prevalence of defined-contribution retirement regimes
could well spark a lasting shift in the preference for saving. That implies
that the days of open-ended spending, without any regard for life-cycle
saving objectives, are drawing to an end.

Nor do I think the corporate turnaround will exactly come in a flash. As
Steve Galbraith continues to stress, earnings disappointments are
lingering in early 2002, even in the face of easy comparisons with a year
ago. That shouldn’t be all that surprising. Business cost structures --
both for labor and fixed capital -- were configured to match the
bubble-induced excesses of the late 1990s. While cost-cutting has been
aggressive over the past year, it has yet to reflect a corporate mindset
that has truly given up the ghost of the bubble. With the macro
numbers now spinning toward recovery, a bit of déjà vu might be all the
more tantalizing. But with the risks still skewed more toward deflation
than inflation -- another key premise of mine that the markets are now
challenging -- I am hard-pressed to believe any recovery in volume will
be vigorous enough to offset the lack of pricing power.

Finally, I remain steadfast in my belief that America’s gaping
current-account deficit is a wake-up call that a US-centric world can no
longer ignore. If left to its own devices, another few years of US-led
global growth could take America’s balance of payments deficit toward
7-8% of GDP. History is utterly devoid of examples when such a
massive external imbalance did not trigger a realignment in relative
growth rates and/or a sharp currency depreciation. I do not believe that
this time will be the sole exception. The dollar is already starting to look
heavy under the weight of the extraordinary volume of external
financing that looms ahead. I fear that’s only the beginning.

I guess what it all boils down to is that I’m still as dumb as ever. Arthur
Burns would have never forgiven me.

morganstanley.com



To: Jim Willie CB who wrote (48573)3/11/2002 3:15:41 PM
From: stockman_scott  Respond to of 65232
 
Fixing Corporate Disclosure

The Washington Post
Sunday, March 10, 2002; Page B08

THE MOST troubling revelation from the Enron affair is that corporate accounts can be meaningless. Companies can conceal their activities in special partnerships that don't get reported to investors, leaving investors no way to assess risks. The Financial Accounting Standards Board, a private rule-writing body, is laboring to close some of these partnership loopholes and may issue a new draft regulation later this month. The signs are that the rule could fall short of what is needed.

At present, a company doesn't have to report a partnership if 3 percent of the partnership's capital is provided by an outside investor. A company can set up a partnership, pump in $97 million of its own cash, and then wheel and deal in secret, so long as somebody else has put up $3 million.

In theory, the $3 million is supposed to be equity capital: The idea is that the third party will be the first to lose if the investments go wrong, and so will object to reckless investments. But this check against secretive risk-taking has had little effect, because outside equity investors have in practice been protected from the usual risks of ownership by tricks of financial engineering.

The board's new rule would strengthen the checks. Rather than having to put up a mere 3 percent of a partnership's capital, third-party investors would have to provide at least 10 percent. Moreover, the tricks that currently shield them from losses would be more explicitly forbidden. A company could still set up a partnership, lend it $90 million and persuade somebody else to put in $10 million. But if the partnership lost money, that somebody else would be on the hook, and the sponsoring company's $90 million would be safe. Unfortunately, the standards board reckons that this means the sponsor's shareholders don't need to be told about the partnership.

This raises two immediate questions.

What is the harm in disclosing the partnerships, even if the Financial
Accounting Standards Board is right that the shareholders' capital is safe?

Second, how safe is it, really? The partnership may hold volatile instruments
that lose more than 10 percent of their value, with the result that all its equity is
wiped out and the loan cannot be repaid in full. The board's experts acknowledge this danger and
urge that partnerships with risky investments have a thicker equity cushion. But urging companies
to be sensible has not worked. The board should spell out exactly how much extra outside
equity is required if risky partnerships are going to be concealed from shareholders.

A further problem: The Financial Accounting Standards Board has yet to decide
how its new rule should treat complex partnerships set up jointly
by several firms to borrow money. These partnerships take in promises
of future payments -- for example, rent payments -- and borrow against
those promises; then they pass the borrowed money back to the sponsoring companies.

This is a way for companies to cleanse their balance sheets
of payment promises and report hard cash instead; it disguises the uncertain
nature of future receipts and the fact that the cash has been
borrowed. The disguise is bad for shareholders. But the banks that
earn large fees for setting up these partnerships are anxious to preserve it.

The Financial Accounting Standards Board is due to discuss its
new rule on March 13, and may circulate a draft soon afterward. A period of
comment will ensue, which is when the battle begins. In the past, lobbyists
have descended upon draft rules, sometimes enlisting congressional
allies to blur disclosure. This time it is essential that the friends of
disclosure -- particularly the institutional investors who hold a large proportion
of corporate stock -- fight equally hard. Stock markets can allocate capital
efficiently only if investors have all the information they need to
understand companies. Without proper disclosure, capitalism can't work properly.

© 2002 The Washington Post Company



To: Jim Willie CB who wrote (48573)3/11/2002 3:36:58 PM
From: stockman_scott  Respond to of 65232
 
Cepheid surges, biotech stocks up

By Ted Griffith, CBS.MarketWatch.com
Last Update: 3:00 PM ET March 11, 2002

NEW YORK (CBS.MW) -- Biotechnology stocks moved higher Monday with shares of Cepheid among the leading advancers after the company said it was developing new systems that could be used in detecting the threat of bioterrorism.

The Amex Biotechnology Index (BTK: news, chart, profile) rose 0.9 percent while the Nasdaq Biotechnology Index (NBI: news, chart, profile) added 0.2 percent in afternoon trading.

Shares of Cepheid (CPHD: news, chart, profile) jumped $1.01, or 34 percent, to $3.97. The Sunnyvale, Calif.-based maker of genetic detection systems said it was working with defense contractor Northrop Grumman (NOC: news, chart, profile) on developing new DNA-based "biothreat detection technology" that could potentially be used by the U.S. Postal Service. However, the companies said the U. S. Postal Service has yet to award the contract.

Shares of Northrop rose $3.02 to $108.94.

Since last year's anthrax exposures on the East Coast, companies, such as Cepheid, whose technologies might be used in defending against biological attacks have been in the spotlight. Coming in the wake of the Sept. 11 terrorist attacks, anthrax-laced letters claimed several lives and heightened fears throughout the nation late in 2001.

Shares of Cepheid climbed as high as $11.48 amid the fears, but the stock has since come back down as investors wonder how lucrative the bioterrorism field will really be.

Overall, since the Sept. 11 terrorist attacks, biotech stocks have had a wild ride. Monday marked six months since the attacks.

By the end of the first week of post-Sept.11 trading, the Amex Biotechnology Index was down 20 percent from its pre-attack level. The biotech index has since mounted a comeback and is now about 2 percent above where it closed on Sept. 10. Some analysts have said there could be more gains in the spring when biotech firms will be highlighting their experimental medications at medical conferences.

Joe Duarte, president of River Willow Capital Management, said he believes investors can do well in biotech, provided they focus on firms that are enjoying a high rate of sales growth with their medications. Duarte said among his current favorites is Genzyme (GENZ: news, chart, profile), shares of which edged up 22 cents to $46.60.

"I'm quite positive on biotech," said Duarte, author of a book called "Successful Biotech Investing." "The sector is acting very well right now."

Elsewhere on Monday, shares of Biogen (BGEN: news, chart, profile) continued to come under pressure, losing $1.05, or 2 percent, to $50.60. Shares of Biogen had fallen sharply Friday after rival Serono said it won U.S. regulatory clearance to sell a drug that will compete with Biogen's flagship multiple sclerosis treatment Avonex. See full story.

After surging Friday, shares of Serono (SRA: news, chart, profile) moved modestly higher Monday, trading up 18 cents to $22.39.

In the pharmaceutical sector, shares of the newly rechristened Wyeth (WYE: news, chart, profile) slipped 66 cents to $61.59 in recent trading.

American Home Products is changing its name effective Monday to Wyeth, to reflect the company's focus on pharmaceuticals. Wyeth-Ayerst Laboratories was the pharmaceutical unit of American Home. The Madison, N.J. -based drugmaker said its new ticker symbol is WYE. The stock will continue to trade on the New York Stock Exchange.

The Amex Pharmaceutical Index ($DRG: news, chart, profile) was virtually unchanged in recent action.

Ted Griffith is a reporter for CBS.MarketWatch.com



To: Jim Willie CB who wrote (48573)3/11/2002 4:20:05 PM
From: stockman_scott  Respond to of 65232
 
STRENGTHENING U.S. ECONOMY WILL BOOST ENERGY DEMAND - BUT BY HOW MUCH?

Mar 11, 2002 (Petroleum Finance Week/PBI Media via COMTEX) -- Recently revised economic figures suggest that the much-ballyhooed U.S. recession was never really a recession at all. But while energy demand obviously benefits from economic strength, it's difficult to predict what impact this news may have on the sector, oil patch economists say.

The news that has economists rethinking the recession is a revised GDP figure that shows 1.4 percent growth in the fourth quarter of 2001, rather than the original estimate of 0.2 percent growth. Bank One - in a research note headlined "The Recession That Wasn't?" - marveled over the growth figures.

"Instead of asking why this economy is so weak, we should all stand in amazement that the U.S. economy weathered the worst inventory bubble in its history, and the extraordinary events of Sept. 11, and was still able to produce growth," wrote Diane Swonk, the Chicago bank's chief economist.

Sarah Emerson, managing director of Energy Security Analysis Inc. in Boston, said that she expects the United States will eventually reach a 3 to 3.5 percent annual economic growth rate, and the rest of the world could reach that figure sometime afterward. At that level of economic growth, global oil demand growth could be expected to rise by approximately 1.75 percent, she suggested.

"That gets you back sometime in 2003 to a growth rate that isn't necessarily the highs of the mid-'90s, but is a fairly sustainable and healthy growth rate," Emerson told Petroleum Finance Week. "The problem is it's easy to make assumptions about the 2003 and beyond period, but we still have this sort of transition year which is 2002."

For 2002, Emerson expects global oil demand to grow by 700,000 barrels per day (b/d), or roughly shy of 1 percent. In comparison, demand growth for oil globally in 2001 rose by just 300,000 b/d. "I think that's a very, very plausible demand growth," she said.

John Felmy, chief economist for the American Petroleum Institute in Washington, looks at the situation product by product. U.S. gasoline demand is very robust right now, perhaps as a function of the economy, but more likely as a function of people's reluctance to fly, he told Petroleum Finance Week. "It looks like gasoline demand [growth] is running above 2 percent right now for the most recent periods," Felmy said.

Of course, more drivers and fewer flyers mean that jet fuel demand is down considerably, approximately 10 percent or so. Felmy thinks the economic rebound may not help that demand as much as the resolution of security concerns and the shortening of long lines at the airport. On the other hand, diesel fuel demand is directly affected by the economy, he continued. "If we see strong economic growth, you're going to see shipments of products and so on," Felmy said. "Because everything travels by truck, that could be a positive influence."

The Energy Information Administration released its latest short-term energy outlook report last week, predicting that total U.S. petroleum demand is expected to recover only after a weak first half of 2002.

"Assuming an economic recovery accelerating in the latter half of the current year and normal weather, [U.S.] demand growth in 2002 is expected to average 60,000 b/d, or 0.3 percent," it said. "But the first half is expected to witness a substantial decline of 340,000 b/d due to continued economic weakness, recent record-warm weather and low natural gas prices."

EIA projects 2002 second half U.S. demand to be approximately 460,000 b/d higher than during the same period last year. Motor gasoline demand should grow by 2 percent this year, following only 1.4 percent growth in 2001 for the entire year as well as the period following the Sept. 11 terrorist attacks. EIA still anticipates that commercial jet fuel demand will be 7 percent lower during 2002's initial six months, but 10 percent higher in the second half.

In 2003, EIA expects domestic petroleum demand to climb by 780,000 b/d, or 3.9 percent, pushed by forecast GDP growth of 4 percent. Globally, EIA projects oil demand growth of 600,000 b/d for 2002, down from the 650,000 b/d projected in last month's outlook. In 2003, it expects global oil demand to grow by 1.4 million b/d - with more than half of that coming from the United States - due to an economic recovery.

Petroleum Finance Week, Vol. 10, No. 10

By Jodi Wetuski in Houston

Copyright 2002 PBI Media, LLC. All rights reserved.